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 Abstract 
Hymenoptera venom allergy is a potentially life-threatening allergic reaction following a 
honeybee, vespid or ant sting. Systemic allergic sting reactions have been reported in up to 
7.5% of adults and up to 3.4% of children. They can be mild and restricted to the skin or 
moderate-to-severe with a risk of life-threatening anaphylaxis. Patients should carry an 
emergency kit containing an adrenaline autoinjector, H1-antihistamines, and corticosteroids 
depending on the severity of their previous sting reaction(s). The only treatment to prevent 
further systemic sting reactions is venom immunotherapy. This guideline has been prepared by 
the European Academy of Allergy and Clinical Immunology’s (EAACI) Taskforce on Venom 
Immunotherapy as part of the EAACI Guidelines on Allergen Immunotherapy initiative. The 
guideline aims to provide evidence-based recommendations for the use of venom 
immunotherapy, has been informed by a formal systematic review and meta-analysis and 
produced using the Appraisal of Guidelines for Research and Evaluation (AGREE II) 
approach. The process included representation from a range of stakeholders. Venom 
immunotherapy is indicated in venom allergic children and adults to prevent further moderate 
to severe systemic sting reactions. Venom immunotherapy is also recommended in adults with 
only generalized skin reactions as it results in significant improvements in quality of life 
compared to carrying an adrenaline auto-injector. This guideline aims to give practical advice 
on performing venom immunotherapy. Key sections cover general considerations before 
initiating venom immunotherapy, evidence-based clinical recommendations, risk factors for 
adverse events and for relapse of systemic sting reaction, and a summary of gaps in the 
evidence.  
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Introduction 
This guideline has been prepared by the European Academy of Allergy and Clinical 
Immunology’s (EAACI) Taskforce on Venom Immunotherapy (VIT) and are part of the 
EAACI Guidelines on Allergen Immunotherapy (AIT). This guideline aims to provide 
evidence-based recommendations for the use of VIT in children and adults. The primary 
audience is clinical allergists although these are also likely to be of relevance to all other 
healthcare professionals (e.g. primary care practitioners, emergency departments and other 
specialist doctors, nurses and pharmacists working across a range of clinical settings) who 
may dealing with insect venom allergic patients.  Development of this guideline has been 
informed by a formal systematic review and meta-analysis of AIT for Hymenoptera venom 
allergy (HVA) with systematic review principles being used to identify additional evidence 
where necessary
1
. 
 
Insects stings by Hymenoptera species are very common with data indicating that 56.6-94.5% 
of the general population has been stung at least once in their lifetime
2
. The most frequent 
clinical presentations of HVA are large local reactions (LLR) at the sting site and systemic 
sting reactions (SSR). A large local reaction has been defined as a swelling exceeding a 
diameter of 10 cm that lasts for longer than 24 hours
3
. In SSR, mild symptoms usually 
manifest as generalized skin symptoms including flushing, urticaria and angioedema. 
Typically, dizziness, dyspnea and nausea are examples of moderate reactions, while shock 
and loss of consciousness, or even cardiac or respiratory arrest all define a SSR. The rate of 
self-reported SSR in European epidemiological studies ranges from 0.3 to 7.5% in adults
4
 and 
up to 3.4% in children
4, 5
.  LLRs occur in 2.4% to 26.4%
6
 of the general population. Severe 
reactions are life-threatening and have been attributed to fatatlities. Although only 0.03 to 
0.48 fatalities/1 000 000 inhabitants/year are reported
2
, Hymenoptera sting mortality may 
7 
have been underestimated due to unrecognized stings in unexplained causes of death. Patients 
with HVA are advised to carry an emergency kit comprising of an adrenaline autoinjector 
(AAI), H1-antihistamines, and corticosteroids depending on the severity of their previous sting 
reaction(s). The only treatment that can potentially prevent further systemic sting reactions is 
venom immunotherapy (VIT), which is reported to be effective in 77-84% of patients treated 
with honeybee venom
7, 8
, in 91-96% of patients receiving vespid venom
7, 8
, and in 97-98% of 
patients treated with ant venom
9, 10
. 
 
The systematic review suggested that VIT is effective in reducing subsequent SSRs reactions 
in both children and adults and that this treatment modality can have a significant beneficial 
impact on disease specific quality of life (QoL)
1
. VIT proved to be safe and no fatalities were 
recorded in the studies included in this review. The cost-effectiveness of VIT needs to be 
established. Modelling cost-effectiveness suggested that VIT was likely to be cost-effective in 
those at high risk of repeated systemic sting reactions and/or impaired quality of life. 
However, primary studies assessing the cost-effectiveness of VIT could not be identified. 
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Methodology 
This guideline was produced using the Appraisal of Guidelines for Research & Evaluation 
(AGREE II) approach
11, 12
, an internationally recognized and accepted structured approach to 
guideline production. This is designed to ensure appropriate representation of the full range of 
stakeholders, a careful search for and critical appraisal of the relevant literature, a systematic 
approach to the formulation and presentation of recommendations and steps to ensure that the 
risk of bias is minimized at each step of the process. The process started in April 2015 beginning 
with detailed face-to-face discussions agreeing the process and the key clinical areas to address, 
followed by face-to-face meetings and regular web-conferences in which professional and lay 
representatives participated. The present guideline is based on the systematic review and they 
follow the methods and criteria applied
1
. 
Clarifying the scope and purpose of the guideline 
The scope of this EAACI guideline is multifaceted, providing statements that assist clinicians in 
the optimal use of use of VIT in the management of patients with Hymenoptera venom allergy 
and identifying gaps for further research. 
Ensuring appropriate stakeholder involvement 
Participants in the EAACI Taskforce on VIT represented a range of 14 European countries and 
disciplinary and clinical backgrounds, including allergists, pediatricians, primary care 
practitioners, ophthalmologists, ear nose and throat (ENT) specialists, pharmacists, 
immunologists, nurses and patient representatives. Representatives of immunotherapy product 
manufactures were given the opportunity to review and comment on the draft guideline as part 
of the peer review and public comment process. These comments were considered by the 
taskforce and, where appropriate, revisions were made.   
Systematic reviews of the evidence 
The initial full range of clinical questions that were considered important were rationalized 
9 
through several rounds of iteration to agree on one key question: what is the effectiveness, cost-
effectiveness and safety of VIT in patients. This was then pursued through a formal systematic 
review and meta-analysis of the evidence
1
. We continued to track evidence published after our 
systematic review and meta-analysis with a cut-off date of July 1, 2017 and, where relevant, 
studies were considered by the taskforce chairs. This evidence will formally be considered in the 
systematic review update that will precede the update of this guideline, which is scheduled for 
publication in 2022.   
Formulating recommendations 
We graded the strength and consistency of key findings from these systematic reviews
1
 to 
formulate evidence-based recommendations for clinical care by applying the GRADE process
13
 
(Box 2). This involved formulating clear recommendations with the strength of evidence 
underpinning each recommendation. Where the systematic review did not cover the clinical area, 
we took a hierarchical approach reviewing other evidence until we could formulate a 
recommendation, i.e.: (i) other systematic reviews on the subject to see if these provided any 
clarity on the topic; (ii) randomized controlled trials (RCTs) within these systematic reviews; 
(iii) other RCTs known to Taskforce members; and (iv) a consensus-based approach using an 
expert panel. Recommendations apply to all ages unless otherwise indicated in the tables. 
Experts identified the resource implications of implementing the recommendations, barriers, and 
facilitators to the implementation of each recommendation, advice on approaches to 
implementing the recommendations and suggested audit criteria that can help with assessing 
organizational compliance with each recommendation.  
Peer review and public comment 
A draft of this guideline was externally peer-reviewed by invited experts from a range of 
organizations, countries and professional backgrounds. Additionally, the draft guideline was 
made available on the EAACI website for a 3-week period in May 2017 to allow a broader array 
10 
of stakeholders to comment. All feedback was considered by the taskforce and, where 
appropriate, final revisions were made in the light of the feedback received. We will be pleased 
to continue to receive feedback on this guideline, which should be addressed to the 
corresponding author.  
Identification of evidence gaps 
The process of developing this guideline has identified a number of evidence gaps which are 
prioritized.  
Editorial independence and managing conflict of interests 
The production of this guideline was funded and supported by EAACI. The funder did not have 
any influence on the guideline production process, on its contents or on the decision to publish. 
Taskforce members’ conflict of interests were declared at the start of the process and taken into 
account by the taskforce chairs as recommendations were formulated. Final decisions about the 
strength of evidence for recommendations were checked by the methodologists who had no 
conflict of interests in this area.  
Updating the guideline 
EAACI plans to update this guideline in 2022 unless there are important advances before then. 
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General considerations before initiating venom immunotherapy 
General indications 
VIT is indicated in children and adults following a systemic allergic reaction exceeding 
generalized skin symptoms with a documented sensitization to the venom of the culprit insect 
with either skin prick tests and/or specific serum IgE tests and/or the basophil activation test 
(BAT). VIT should also be considered for adults with skin symptoms only but at high risk of re-
exposure and/or impairment in QoL.  VIT is not indicated if no sensitization to insect venom can 
be verified. Also, an incidental finding of sensitization to insect venom (e.g. using a multiplex 
system) in patients who have not had a SSR is not an indication for VIT.  Furthermore it is not 
indicated in patients with unusual reactions that cannot be attributed to Type I immediate 
reactions such as thrombocytopenic purpura and vasculitis, rhabdomyolysis or renal failure after 
multiple stings. The risk for future systemic reactions is low in patients with LLR, in whom only 
0.8-7% are expected to develop SSR in the future
14-16
. As patients with repeated LLRs have been 
reported to have a minimal risk for SSR
17, 18
, VIT is generally not recommended in these 
patients. However, subcutaneous VIT has been shown to reduce the size and duration of LLR
19
. 
Therefore, VIT could be considered a treatment option in patients with recurrent, troublesome 
LLRs. Additional precautions should be taken to avoid insect stings during the build-up phase of 
VIT by following preventive measures such as not going barefoot, not eating outdoors and 
avoiding gardening. Beekeepers should stop beekeeping until the maintenance dose is reached 
because of the increased risk of stings and consecutive SSR (Table 1). 
Absolute and relative contraindications and VIT in patients with special conditions 
An European position paper on clinical contraindications has been in 2015 published tackling all 
relevant contraindications in detail
20
. In a recently published survey among 520 mainly 
European allergists, up to 47% had experience with administration of AIT in patients with risk 
conditions such as cardiovascular disease, taking ACEI or beta-blockers, malignant disease in 
12 
remission, and autoimmune disease which previously had been considered as 
contraindications
21
. Problems were uncommon and mostly minor so we have reconsidered 
contraindications in VIT.  Below contraindications are briefly described, and recommendations 
are given in Table 2.  
Cardiovascular disease 
Fatality studies have shown that particularly elderly patients with HVA and pre-existing 
cardiovascular disease have an increased risk of dying from a sting
22
. Therefore, in contrast to 
respiratory allergies, VIT is commonly performed in elderly patients. Based on the risk / benefit 
profile, cardiovascular diseases per se are not a contraindication for VIT
20
. 
Beta-blockers 
There is good evidence that anaphylaxis does not occur more frequently in patients receiving 
beta-blockers, as recently summarized in an EAACI position paper
20
. However, these patients 
may theoretically be at increased risk of more SSRs, and emergency treatment with adrenaline 
may be less effective. Elderly patients with HVA and cardiovascular disease treated with beta-
blockers are considered to be particularly at high risk of severe SSR in the case of an insect 
sting
23
. Based on the risk/benefit profile, there is no contraindication for VIT in patients treated 
with beta-blockers
20
.   
Angiotensin-converting enzyme inhibitors (ACEI) 
Studies with large number of patient participants conclude that treatment with ACEI does not 
affect the safety of VIT
24, 25
. One study reported a higher risk for more severe SSR
26
, however 
there is a growing base of evidence that indicates that ACEI do not increase the risk for severe 
SSR in untreated patients
27-29
. In univariate analyses, results are often confounded by patient’s 
older age which has been shown to be a strong risk factor for more severe SSR
27, 29, 30
. One 
multicenter study reported that all patients on ACEI tolerated a sting challenge or field sting 
during VIT
31
, whereas in another study patients taking ACEI had a higher risk for relapse
32
. 
13 
However, the risk of ACEI may have been overestimated in certain studies due to the very small 
patients’ group and highly selected patients with suggested cardiovascular comorbidity33. 
Therefore, ACE inhibitor therapy may be continued during VIT, but the patient should be 
informed about possible risks 
Malignant neoplasia 
AIT was safely administered in patients suffering concomitantly from vespid venom allergy and 
less advanced stage cancer in one small case series of four patients
34
. No controlled studies are 
available relating to the risk or effectiveness of AIT are available in malignant neoplasias
20
. 
Therefore, acute malignant neoplasias are considered a relative contraindication, even if there is 
no evidence on any unfavourable effects of VIT on tumor growth or the efficacy of 
chemotherapy. The benefits of VIT should be weighed against the possible burdens of the 
treatment and the activity of the tumour disease. To conclude, VIT can be recommended in high 
risk venom allergic patients when malignant disease is stable or in remission. 
Autoimmune disorders 
Caution should be exercised when prescribing VIT to patients with multi-organ autoimmune 
disorders. Due to a lack of available data, there is a relative contraindication in autoimmune 
disorders in remission and an absolute contraindication in active forms
20
. Organ-specific 
autoimmune disorders, such as e.g. diabetes mellitus, Hashimoto’s thyroiditis, Crohn’s disease, 
ulcerative colitis, and rheumatoid arthritis are not considered a contraindication when the disease 
is stabilized, but concerns were raised that immune-suppressive medication could theoretically 
negatively influence the effectiveness of VIT
35
. Therefore, VIT can be recommended in patients 
with organ-specific autoimmune disorders when the underlying disease is stabilized 
Monoamine oxidase inhibitors (MAOI) 
The prescribing of MAOIs is now extremely limited, due to their wide range of dangerous drug-
drug interactions
36
. The major concern with their use in the context of AIT is that they prevent 
14 
the breakdown of sympathomimetic drugs; therefore, in the event of adverse events emergency 
treatment with adrenaline could result in severe hypertension and/or tachycardia
20, 36
. To 
conclude, treatment with MAOIs is not a contraindication for VIT but caution is recommended 
with the use of adrenaline 
Children below five years of age 
Generally, severe SSR are less frequent in children, and appear to be rare in children of 
preschool age (<5 years)
37
. In the rare event of a SSR, decisions should be made on an individual 
basis considering the risk of future severe systemic reactions. Successful VIT in children under 
four years have been reported
38
; as the age limit of five years is arbitrary, there are no specific 
concerns regarding children younger than five years and the same recommendations as in adults 
apply.  
Pregnancy 
The incidence of prematurity, toxemia, abortion, neonatal death and congenital malformation 
appears to be similar in patients on AIT during pregnancy compared to the general population
39
. 
During VIT only two mild adverse events were observed in 43 pregnancies
40
. VIT appears to be 
safe in pregnant women, but data are scarce. Therefore, initiation of VIT is not recommended. 
Due to the high risk of relapse after early termination of VIT
41, 42
 and the low risk of adverse 
events
24, 43
, a well-tolerated ongoing VIT regime during pregnancy should be continued, using 
the tolerated VIT maintenance dose administered before pregnancy. 
Mastocytosis 
Mastocytosis is a risk factor for both the development of HVA and for more severe SSR
44
. VIT 
is usually well tolerated by the majority of patients with underlying systemic mastocytosis
45
, 
although adverse events can occur more frequently
46
.  In a recent large study on patients with 
confirmed systemic mastocytosis and severe initial sting reactions (63% suffered from loss of 
consciousness), it could be shown that VIT was safe and effective
47
. Whether elevated serum 
15 
tryptase levels alone increase the risk for adverse events is still a debated issue and robust data 
are scarce. One study showed a slightly elevated risk for adverse events
24
, whereas others did not 
identify a higher risk
25
 which may be related to a very low overall rate in objective side effects in 
all patients. Generally, there is no evidence from the literature that VIT should be performed 
indefinitely in patients with mastocytosis
48
. However, VIT may be less protective in patients 
with severe initial SSR and mastocytosis and/or elevated serum tryptase ( >11.4 µg/L). 
Therefore, for safety reasons, it should be prolonged in those patients; it remains unclear whether 
it should be given life-long or after which duration of treatment it should be stopped. 
Quality of life 
For most patients, and their families, any allergic reaction (regardless of severity) is a frightening 
experience. Given the effort required to avoid accidental exposures and the inherent uncertainty 
of success, living with HVA negatively influences QoL. This is particularly due to emotional 
distress of being alert during activities of daily living
49
. VIT improves QoL in vespid venom 
allergic patients even when they do not experience a re-sting
50
. In a study where patients were 
offered a sting challenge after VIT, 80% of patients reported a significantly increased QoL after 
tolerating a sting challenge
51
. In contrast, therapy with the AAI alone was shown to negatively 
impact on health related QoL
50, 52
, a significantly increased burden for patients
53
 and a higher 
level of anxiety and depression
54
. In contrast, more than 90% of patients perceived VIT as 
(extremely) positive
53
, with health and allergy-related QoL improving significantly during 
treatment
50, 52, 55
, dysfunctional beliefs decreasing
55
 and anxiety and depression levels were the 
lowest among VIT treated subjects
54
.  In a randomized study evaluating dermal reactors,  QoL 
was also impaired in these systemic reactors and VIT was also able to improve their QoL in 
contrast to the AAIs
52
. 
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Venom immunotherapy: evidence based clinical recommendations 
 
Available venoms 
Venom of Apis mellifera and Vespula species is available throughout Europe, whereas venom of 
Polistes is accessible in those countries where allergy to Polistes species (e.g. Polistes dominula 
in Spain and Italy) is most often occurs. The use of bumblebee venom would be preferable if the 
primary sensitization was induced by bumblebee stings
56, 57
. Bumblebee venom for VIT is 
currently only available in some countries, e.g. in Italy.  Worldwide, also ant venoms are 
available, such as venom of Myrmecia pilosula (Jack Jumper Ant) in Australia. 
Preparation of venom 
Throughout Europe, non-purified aqueous, purified aqueous preparations and purified 
aluminium hydroxide adsorbed preparations (so-called “depot” preparations) are used to perform 
subcutaneous VIT
58. The efficacy is supported by studies using both sting challenge and ‘in-
field’ stings58. The aqueous preparations can be used for build-up protocols including ultra-rush, 
rush, clustered and conventional, as well as for maintenance phase. Purified aluminium 
hydroxide adsorbed preparations are typically used for the conventional or clustered build-up 
and maintenance schedule. Treatment can be switched from aqueous to depot preparations 
following the rapid up-dosing phase
59
. Depot preparations seem to be associated with fewer local 
side effects than aqueous preparations, but results may have been biased by the slower build-up 
phase with depot preparations
60
. Purified aqueous preparations cause smaller local reactions 
compared with non-purified aqueous preparations 
61
. A systematic literature review has 
documented a similar rate of systemic adverse events when depot and aqueous venom allergen 
preparations were used, but the difference between purified and non-purified aqueous 
preparations was not taken into account
62
. A comparative study in honeybee venom allergic 
patients indicates the superiority of the purified aqueous preparations over the corresponding 
17 
non-purified aqueous preparation under the same rush protocol in terms of systemic reactions 
during the build-up phase
63
 (Table 3). 
Treatment with more than one venom 
Selection of the correct venom preparation(s) is important to ensure optimal efficacy of VIT. 
Sensitization to venom of more than one Hymenoptera species is common in insect venom 
allergic patients
64
 and it can be difficult to determine whether this reflects double sensitization 
due to cross-reactivity of shared allergenic determinants or genuine multiple sensitization to 
more than one venom. However, in most of these cases treatment with only one venom appears 
to be sufficient
64
. A major diagnostic problem is that currently available tests, such as skin 
testing, IgE determination including component-resolved diagnosis or the BAT are not able to 
distinguish between asymptomatic sensitization and clinically relevant allergy with LLR and 
SSR
18
. However, if the initial sting reaction was severe and all allergy tests are almost equally 
positive to vespid and to honeybee venom, VIT with both venoms should be considered. As 
there is only limited cross-reactivity between honeybee and vespid venom and Vespula and 
Polistes venom, simultaneous injections with both venoms should be safe. This approach is 
common in the United States (US) and partly in Europe, however, no studies have examined this 
question (Table 3).  
Preventive pre-treatment 
In several double-blind, placebo-controlled trials, it has been shown that pretreatment with H1 
antihistamines improves the tolerability of VIT
65-68
. In detail, it was reported that levocetirizine 
decreased the rate of  SSR
68
 and fexofenadine decreased the rate of LLR and cutaneous SSR
67
 
(Table 3). Importantly, effectiveness of VIT was not negatively influenced
68, 69
. Antihistamines 
were usually administered 1-2 hours before the injections or sometimes twice daily. In case of 
repeated adverse events during up-dosing, pre-treatment with Omalizumab may be 
recommended
70-72
. 
18 
Treatment protocols 
VIT is performed by subcutaneous injections. VIT consists of an up-dosing phase and a 
maintenance phase, which is necessary to ensure a sustained effect of VIT. Conventional 
protocols, where the maintenance dose is reached in several weeks to months, can be 
administered in outpatient clinics
73
. In an effort to reach the maintenance dose faster, rush 
73-77
 
and ultra-rush protocols
78-81
 with several injections per day on consecutive days are performed in 
hospitals. Maintenance dose is reached either within a few hours or within a few days, 
respectively. Cluster protocols, with several injections per day usually 1-2 weeks apart, are also 
a quick alternative to conventional protocols
82, 83
. Importantly, the risk of adverse events is not 
associated with the severity of initial reactions
24, 25, 84
, high venom-specific IgE levels, or skin 
test reactivity at low venom concentrations
84, 85
. Conventional regimes appear to be best 
tolerated while rush and ultra-rush protocols are more frequently associated with adverse 
events
24
.  
Up-dosing  
The recommended starting dose in up-dosing protocols lies between 0.001 and 0.1μg, but it has 
also been shown that a starting dose of 1μg is usually safe and not associated with a higher rate 
of side effects in adults or in children
86
. A maximum dose of 100μg venom allergen dose usually 
offers adequate protection against systemic allergic sting reactions in the majority of venom 
allergic individuals
87-89
.  
Maintenance dosing 
A maintenance dose of 100µg venom is significantly more effective than 50 µg 
88
. This dose is 
equivalent to the dry weight of approximately two honeybee stings or five wasp stings
90
 and has 
been adhered to as the recommended maintenance dose since the first controlled trial
87
. A further 
increased dose gives a better protection when needed
91
. A dose of 200μg is recommended in 
patients who develop systemic allergic reactions following a field sting or sting challenge while 
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on 100μg maintenance VIT91. An increased maintenance dose should also be considered in 
allergic populations at high risk of multiple stings, such as beekeepers
92
 and in exceptional cases 
where patients have accumulated risk factors for treatment failure.  
Although the European Medicines Agency (EMA) had no safety concerns regarding aluminium 
toxicity from their pharmacovigilance review of aluminium hydroxide in standard AIT, high 
dose VIT and life-long therapy has not been specifically evaluated. As a precaution, where life-
long therapy is planned is can be undertaken with aqueous preparations. If a 200µg dose is 
required for maintenance, half can be given as an aqueous preparation.   
The interval for maintenance VIT with 100μg venom recommended by the manufacturers has 
been 4-6 weeks for aqueous preparations and 6-8 weeks for purified aluminium hydroxide 
adsorbed preparations (depot preparations). According to expert consensus, injections are 
usually given every four weeks in the first year of treatment, every six weeks in the second year, 
and in case of a five year treatment every eight weeks from year 3-5
93
. Extending the 
maintenance interval to three months does not seem to reduce effectiveness or increase adverse 
events
94-96
, which could be relevant in terms of convenience and economic savings if life-long 
treatment is necessary. As there is no specific study available for mastocytosis patients with 
severe initial SSR, caution should be used in extending the intervals to three months in those 
patients. A dose interval of six months did not provide suitable protection in honeybee venom 
allergic patients
97
 and is therefore not recommended for standard practice (Table 3).  
Duration of VIT 
Termination after approximately one or two years leads to a relapse rate of 22-27% 
41, 42
. Some 
studies have concluded that VIT for three years may be sufficient
98
, particularly in patients with 
only mild to moderate initial sting reactions
98
. Nevertheless, most of the studies concluded that a 
minimum of a five-year treatment is superior for long-term effectiveness
99-102
. Life-long therapy 
should be considered in patients with severe initial SSR, systemic adverse events during VIT, 
20 
and honeybee venom allergic patients with high risk of future honeybee stings (Table 3, 4).  
 
 
 
Adherence 
Adherence to VIT is high, possibly because of patients’ perception of an unpredictable risk of 
life threating sting reactions. In a recent study 95% and 84% of patients still continued VIT after 
three and five years, respectively
103
. 
Effectiveness 
Treatment with ant venom is very effective as 97 to 98% are protected after VIT
9, 10
. The 
effectiveness of honeybee and vespid VIT is different and ranges from 77 to 84% for honeybee 
venom compared to 91 to 96% for vespid venom
7, 8
. The underlying reasons are still unclear. It 
has been speculated that the amount of venom delivered by a honeybee sting is much larger and 
more consistent
90
. This may also explain the difference in the reaction rate to sting challenges, 
which has also been observed in untreated patients
104-106
. It also appears that the broad 
sensitization pattern in honeybee venom allergic patients may play a role in the lower 
effectiveness of honeybee VIT
107
. For example, some patients are predominantly sensitized to 
Api m 10, which may be underrepresented in certain available honeybee venom preparations
108, 
109
. However, none of these studies included a patient analysis of molecular sIgE binding 
patterns to honeybee venom allergens before the start of VIT. Without such a specific IgE 
stratification aligned with the clinical outcome, the conclusions are of limited value. The specific 
preparation does not seem to have an impact on the effectiveness. The effectiveness of aqueous 
and purified aluminium hydroxide adsorbed preparations has been shown to be similar
60, 110
.  
Effectiveness of VIT after up-dosing phase 
Only one recent study has looked at how rapidly protection occurs. In honeybee VIT, 89% 
21 
tolerated the sting challenge one week after reaching the maintenance dose in a 3-5 day rush 
protocol or a 3-4 month conventional protocol. Those patients who were not protected with 
100µg venom, tolerated the sting challenge immediately after reaching the dose of 200µg
89
.  
Effectiveness during/after maintenance VIT 
Most effectiveness data are obtained during VIT. Re-sting reaction rates of 0-10% 1-5 years 
after discontinuation of vespid VIT have been reported 
100, 101, 111
. Relapses after honeybee VIT 
are more frequent as 17% are reported to relapse one year after stopping VIT
112
. There are only 
few reports on the outcome following VIT withdrawal for more than five years, and there are no 
data for more than 10 years after discontinuing VIT. In two studies 7-7.5% of patients treated  
with vespid venom relapsed after 7 to 10 years
98, 99
, while 15.8% after stopping honeybee VIT 
had re-sting reactions
99
. Another study compared relapse rates after four and approximately 10 
years and reported relapse rates of 10.2% and 16.2%, respectively
113
. In children, the long term 
outcome is superior compared to adults as only 5% with moderate-to-severe reactions relapsed 
after up to 20 years after stopping VIT
15
. 
Carriage of adrenaline auto-injectors during and after VIT 
It is still a debated issue whether AAI should be carried during and after VIT, and it has also 
been difficult to reach a consensus on this topic. Most patients are protected after reaching the 
maintenance dose
89
. Therefore, patients usually do not need to carry AAIs at this point, 
particularly if their sting reaction had been mild or they had tolerated a sting challenge or field 
sting during VIT.  It should also be considered that carrying an AAI can negatively impact on 
health-related QoL
50, 52
 (Table 3). According to the EAACI position paper “Self-medication of 
anaphylactic reactions due to Hymenoptera stings”, 13% of experts/authors would still prescribe 
an AAI to patients who initially only had generalized skin symptoms after discontinuation of 
VIT; and 100% considered recommending carrying an AAI in patients who initially suffered 
22 
from moderate-to-severe reactions after terminating VIT if risk factors for treatment failure were 
present
114
.  
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Risk factors for systemic adverse events with VIT and relapse of SSR 
Risk factors for systemic adverse events with VIT 
The frequency of systemic adverse events with VIT in large multi-center studies ranges from 8-
20%
24, 43, 84
. Several risk factors for the occurrence of systemic adverse events have been 
described. Most of the studies include only small numbers of patients and provide conflicting 
data. The most important risk factor is treatment with honeybee venom. It has been consistently 
reported that there is a 3.1 to 6.0-fold higher risk for systemic adverse events due to treatment 
with honeybee venom
24, 77, 86
. Rapid dose increase during the build-up phase is a weaker, but 
nonetheless established risk factor
24, 43
.  Mastocytosis and/or elevated serum tryptase was 
initially considered as risk factor for adverse events. An EAACI multicenter study found a 
slightly elevated risk when tryptase was elevated in vespid venom allergic patients (OR 1.56; CI 
1.15-2.10)
24
, whereas another study performed in honeybee venom allergic patients did not
85
. A 
study performed in patients with mastocytosis concluded that VIT is safe and efficacious
47
, 
confirming previous data
45
. Although still a debated issue, ACE inhibitors and beta-blockers are 
not considered to be independent risk factors for adverse events
23-25
. Importantly, severe initial 
sting reactions
24, 25, 84
, positive skin tests at low test concentrations and high specific-IgE levels
25, 
84, 85
 are not regarded as risk factors for adverse events (Table 4).  
Management of adverse events during build-up phase of VIT 
Adverse events are generally mild and adequately respond to standard anti-allergic treatment
20, 
36
. In the case of systemic adverse events, a common procedure during build-up phase is 
reducing the allergen dose (going one to two steps back in the protocol) and then continuing with 
the second last well tolerated dose of VIT. If not yet considered, premedication with H1 
antihistamines should be established. When systemic adverse events prevent reaching the 
maintenance dose, premedication with Omalizumab may be an option. Currently, case reports 
24 
and a case series have documented the usefulness of Omalizumab
70-72, 115
 but there is also one 
negative report
116
 (Table 4).  
 
Risk factors for relapse of SSR (Table 4) 
Age and type of venom 
As already mentioned above, children generally have a more favorable prognosis than adults
15
, 
and patients who were treated with honeybee venom had a higher risk for relapse compared to 
those who were treated with vespid venom
98, 99, 113
.  
Severity of reaction prior to VIT 
Two studies reported a higher relapse rate in patients who have had a severe SSR before VIT
98, 
100
.  In the larger study, relapses were observed in 4% with mild but 14% with severe 
pretreatment reactions
98
. Other studies concluded that the grade of the SSR prior to VIT was not 
relevant to the probability of a relapse
112, 117
. Although it is still controversial whether severe 
initial SSR are a risk factor for relapse, it has been agreed that those patients are at greater risk 
for severe SSR when they relapse
118
.  
Systemic adverse events during VIT 
Patients who developed systemic allergic adverse events during  VIT showed a relapse risk of 
38%, while those who did not, only had a 7% risk
112
. Two more studies reported similar results 
(46% vs. 8% and 16.4 vs. 5.4%, respectively)
32, 102
. 
Mastocytosis/elevated serum tryptase levels 
A large multicenter study could not detect an association between higher baseline tryptase and 
therapy failure
31
, and 86% of 50 mastocytosis patients were protected after initiation of VIT
47
. 
However, one study indicated that patients with tryptase >20 µg/L and/or mastocytosis in the 
skin had a 2.7-fold higher risk for therapy failure
32
. Available data are scarce and heterogeneous 
25 
but it appears that mastocytosis is not a strong general risk factor for relapse but should be 
considered as risk factor in individuals with severe initial SSR.  
 
 
ACEI 
While in one multi-center study all patients on ACEI tolerated a sting challenge or field sting 
during VIT
31
, another study reported a higher risk for relapse in patients taking ACEI 
32
. 
However, the risk of ACEI might have been overestimated due to the very small patients’ group 
and highly selected patients with suggested cardiovascular comorbidity
33
.  
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Procedures to monitor VIT 
Many attempts have been made to identify biomarkers to monitor AIT. In peripheral venous 
blood samples of treated patients, there are significant changes of venom-specific T cell 
populations, secreted cytokine patterns and immunoglobulin levels but these are not appropriate 
to estimate the individual risk for relapse of SSR. The sting challenge remains the gold standard 
in identifying unprotected patients (Table 5).  
Sting challenges / field stings 
Performing sting challenges is still the most reliable method and gold standard to monitor the 
effectiveness of VIT. VIT is effective immediately after reaching the first maintenance dose
89
. 
Therefore, if feasible, sting challenges should be performed as early as possible to identify those 
who are not protected with the maintenance dose of 100µg. If sting challenges cannot be 
performed, information about field stings may be helpful. However, the risk of misidentification 
of the stinging insect and the non-standardized sting procedure reduce reliability
112
.  
The reproducibility of sting challenges, at least for diagnostic purposes, is a debated issue. A 
study on 129 patients revealed that in 95% of patients a diagnostic sting challenge provided a 
good prediction of tolerance for subsequent field stings
119
. On the other hand, it has been shown 
that 21% of patients not treated with VIT, who initially tolerated a sting challenge, had systemic 
symptoms after a second challenge
120
. The reliability of early sting challenges to monitor 
effectiveness of VIT appears to be high
121
, although repeated sting challenges during three to 
five years after treatment identified 8-10% of patients who relapsed
101, 117
. Importantly, tolerated 
sting challenges can improve health related QoL, especially in patients reporting high 
impairment of health related QoL before the sting challenge
51
. Thus, sting challenges should not 
only be seen in the context of evaluating effectiveness but also in terms of fostering individual 
belief in disease-specific safety. 
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Specific-IgE and IgG4 levels 
It has been repeatedly shown that specific-IgE levels to the respective venom decrease during 
VIT after an initial rise during the first months of treatment
60, 121
; they usually remain low even 
after stopping VIT
117
. VIT is associated with a significant increase in specific IgG antibodies that 
has initially been suggested as a marker of effectiveness
122
; these immunological changes induced 
by VIT were also reported in honeybee venom allergic children
123
. The sub-class of IgG 
antibodies is usually restricted to IgG1 and IgG4
121
. However, after stopping VIT, specific IgG 
starts to decrease
99, 124, 125
 and patients appear to be protected by a mechanism independent from 
venom-specific IgG
122
. Taken together, available data do not support the use of specific IgE, 
specific IgG or specific IgG subclasses or even ratios can be used as predictors for protection 
during and after VIT in the individual patient.  
Intradermal testing 
Similar to the decline of specific IgE levels during VIT, intradermal test endpoint concentrations 
usually decrease from before to after VIT
99, 101
. No study has been able to identify a relevant 
difference in skin test reactivity between tolerant subjects and patients with relapses
99, 100, 112
. 
Moreover, patients with negative intradermal tests have been reported to have significant 
relapse, a few with near fatal reactions
102, 113
. 
Basophil activation test (BAT) 
Allergen-specific basophil response remains positive
126
 or even unchanged
125
 during VIT. 
However, basophil responses at submaximal allergen concentrations are markedly decreased 
after VIT in tolerant subjects and this decline seemed to be associated with the induction of 
tolerance
125, 127
. Also the measurement of basophil threshold sensitivity to anti-FcεRI stimulation 
has been proposed to monitor an early protective effect of VIT
128
. BAT inhibition with sera of 
treated subjects correlated well with effectiveness of AIT in grass pollen allergic patients
129
 but 
this has not yet been shown in patients with HVA.  
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Enzyme-linked immunosorbent facilitated antigen binding (ELIFAB) 
The ELIFAB is a cell-free assay which is used to demonstrate inhibition of allergen-specific IgE 
binding by blocking antibodies
130
. One study measured the serum inhibitory activity of VIT-
treated vespid-venom patients
124
. During VIT, patients displayed an increased ability to inhibit 
Ves v 5 binding by IgE antibodies. This allergen-blocking capacity correlated with serum 
concentrations of Ves v 5-specific IgG4. However, both the inhibitory activity and specific IgG4 
levels were again reduced in patients who stopped VIT several years ago
124
.  
Despite of the availability of new methods such as the BAT and the ELIFAB, most of the 
parameters cannot precisely distinguish between patients who are protected from future SSR and 
those who are at risk. Currently, it is not possible to estimate the individual risk for relapse of 
SSR with any of the currently available parameters (Table 6). 
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Summary, gaps in the evidence and future perspectives 
The EAACI Taskforce on VIT has developed this guideline as part of the EAACI AIT 
Guidelines initiative. The guideline have been informed by a formal systematic review and meta-
analysis of VIT
1
. The guideline provides evidence-based recommendations for the use of VIT 
for patients with LLR and SSR. A summary of the guideline is provided in Box 3 and key 
messages for primary care practitioners are given in Box 4. The recommendations should be of 
value to all healthcare professionals involved in the management of patients with HVA.  
There are a number of areas in this guideline where high-quality evidence is not available. The 
primary gaps are highlighted here and in Table 6. There is a major gap in the evidence for the 
clinical effectiveness of VIT in children and adolescents with recommendations at least one 
grade lower than for adults in most areas. Contrary to anecdotal findings, an important number 
of children do not outgrow allergic reactions to insect stings
15
. Additionally, the effect of VIT in 
children and their parents on health-related QoL should be investigated further. In adults, there is 
need for studies with sufficient power to evaluate risk factors for adverse effects during VIT or 
for treatment failure. There is also minimal data in the elderly population particularly for patients 
with cardiovascular disease. Additionally, we need cost-effectiveness and cost utility studies to 
use in discussions with healthcare funders. Biomarkers to predict effectiveness of VIT and to 
identify treatment failure are also urgently needed. 
Despite all these gaps, we have clear evidence for the clinical effectiveness of VIT for patients 
with SSR. Potential barriers and facilitators for the implementation of these recommendations 
are described in Table 7. There is now a need to ensure that primary care healthcare 
professionals know which patients might benefit from VIT, that national healthcare providers 
understand that VIT is highly effective and is likely to be cost-effective, and that patients and 
patient support groups are aware of this approach.   
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Box 1. Key terms 
Allergen 
immunotherapy (AIT) 
Repeated allergen administration at regular intervals to modulate immune 
response in order to reduce symptoms and the need of medication for 
clinical allergies. This is also sometimes known as allergen specific 
immunotherapy, desensitization, hyposensitization, or allergy vaccination 
Aqueous venom 
preparations 
Lyophilized venom, which is reconstituted in (albumin-containing) saline 
diluent. 
Depot venom 
preparations 
Venom preparation adsorbed onto aluminium hydroxide or L-tyrosine. 
Purified venom 
preparations 
Venom preparations where irritant low-molecular components <1000 
Dalton are removed. 
Venom immunotherapy 
(VIT) 
AIT where insect venom preparations are administered as a series of 
subcutaneous injections to eliminate systemic allergic reactions after 
insect stings.  
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Box 2: Assigning levels of evidence and recommendations [Oxford Centre for 
Evidence-based Medicine] 
Level of evidence 
Level I  Systematic reviews, meta-analysis, randomized controlled trials 
Level II  Two groups, nonrandomized studies (e.g., cohort, case–control) 
Level III  One group nonrandomized (e.g., before and after, pretest, and post-test) 
Level IV  Descriptive studies that include analysis of outcomes (single-subject design, 
case series) 
Level V  Case reports and expert opinion that include narrative literature, reviews, and 
consensus statements 
Grades of recommendation 
Grade A     Consistent level I studies 
Grade B     Consistent level II or III studies or extrapolations from level I studies 
Grade C     Level IV studies or extrapolations from level II or III studies 
Grade D     Level V evidence or troublingly inconsistent or inconclusive studies at any level 
Strength of recommendations 
Strong       Evidence from studies at low risk of bias /high quality studies 
Moderate  Evidence from studies at moderate risk of bias /moderate quality studies 
Weak        Evidence from studies at high risk of bias /low quality studies 
 
Recommendations are phrased according to the strength of recommendation: strong: “is 
recommended”; moderate: “can be recommended”; weak: “may be recommended in 
specific circumstances”; negative: “can not be recommended”.  
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Box 3 Summary 
 
 VIT is recommended in children and adults with detectable sensitization and systemic sting 
reactions exceeding generalized skin symptoms. 
 VIT is recommended in adult patients with systemic sting reactions confined to generalized 
skin symptoms if quality of life is impaired 
 VIT is not recommended in individuals with incidentally detected sensitization and no 
systemic symptoms 
 Patients with severe initial sting reactions, high skin test reactivity, and high venom specific 
IgE levels are not associated with a higher risk of adverse events 
 Pre-treatment with H1 antihistamines is recommended as it reduces large local reactions 
and to some extent also systemic adverse events 
 VIT should be performed for at least three years. In patients with severe initial sting 
reactions, at least a five year treatment is recommended 
 Life-long VIT may be recommended in highly exposed patients with honeybee venom 
allergy, patients with very severe initial sting reactions (Muller grade IV or grade III-IV 
according to Ring & Messmer), and patients with systemic side-effects during VIT as they 
are major risk factors for relapse 
 All available diagnostic tests, including determination of venom specific IgE, IgG, BAT 
response and allergen-blocking capacity, are not able to estimate the individual risk for 
relapse 
 Sting challenges are the most reliable method to evaluate effectiveness of VIT 
43 
Box 4 Key messages for primary care practioners about referral to allergy services 
for venom immunotherapy 
- Venom immunotherapy is very effective in preventing future systemic reactions to 
honeybee, wasp, and ant stings 
- Refer patients to an allergist with experience in venom immunotherapy for assessment     
as below. If unsure on review seek advice from your local allergy centre 
- Venom immunotherapy is recommended in individuals with 
- systemic sting reactions exceeding generalized skin symptoms 
- generalized skin symptoms only (including urticaria/angioedema) if 
quality of life is impaired 
- Venom immunotherapy is not recommended in individuals with 
- only local reactions, including large ones (defined as a swelling 
exceeding a diameter of 10 cm lasting longer than 24 hours) 
- incidentally detected sensitization and without any systemic allergic 
symptoms 
-  A careful personal history should be taken (culprit insect, characterization of sting 
reactions, emergency and concomitant medication) and, if possible, venom specific-IgE 
should be determined before patients are referred to an allergist 
-  Negative test results are possible in patients with insect venom allergy. If there were 
clear symptoms of anaphylaxis after a sting, patients should be referred to an allergist 
- Large local reaction typically develop within 24 hours and should be treated with oral 
antihistamines and corticosteroids but not oral antibiotics. No further follow-up is needed. 
- Quality of life is impaired in many patients who only carry an adrenaline autoinjector and 
do not receive venom immunotherapy 
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Table1. Recommendations: indications for VIT 
Recommendations for 
individuals with venom allergy 
Evidence level 
Grade of 
recommendation 
Strength of recommendation  
Other considerations 
Key 
references 
VIT is recommended in adults and 
children with detectable 
sensitization and systemic sting 
reactions exceeding generalized 
skin symptoms 
I 
 
(III for children) 
A  
 
(B for children) 
Strong-to-moderate for adults 
based on two high quality SR.
1
 
131
 
Weak for children based on one low 
quality CBA
15
 and one low quality 
RCT study that included children
87
 
Carrying an AAI without VIT 
negatively impacts on health-
related QoL  
Dhami 2017
1
 
Boyle 2012
131
 
Golden 2004
15
 
Hunt 1978
87
                              
VIT is recommended in adult 
patients with systemic sting 
reactions confined to generalized 
skin symptoms if quality of life is 
impaired 
I A 
Strong-to-moderate based on one 
high quality SR
1
 and two adult 
RCTs of moderate quality
50, 52
 
Carrying an AAI without VIT 
negatively impacts on health-
related QoL 
Dhami 2017
1
 
Oude Elberink 
2002 and 
2009
50, 52
 
VIT can be recommended in 
adults with recurrent, troublesome 
LLR to reduce the duration and 
size of future LLR 
II B 
Moderate/low based on one open, 
controlled trial of venom allergic 
adults with LLR
19
 
Cost/benefit profile should be 
considered for this indication. 
No pediatric data 
Golden 2009
19
 
 
VIT is not recommended in 
individuals with incidentally 
detected sensitization to insect 
venom and no clinical symptoms 
IV C 
Weak based on one case series 
and expert consensus
18
 
Asymptomatic sensitization is 
very common 
Sturm 2014
18
 
VIT is not recommended in 
patients with unusual reactions 
that do not represent immediate 
type systemic reactions 
V D 
Weak, as no studies have focused 
on this. Expert consensus 
Reactions of non-allergic 
nature following Hymenoptera 
stings require neither 
diagnostic testing nor 
administration of VIT 
Expert 
consensus 
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Table 2. Recommendations: VIT in patients with special conditions 
Recommendations for individuals with 
venom allergy 
Evidence 
level 
Grade of 
recommendation 
Strength of 
recommendation  
Other considerations Key references 
VIT can be recommended in patients with 
cardiovascular disease but the underlying 
disease should be stabilized before initiation 
V D 
Weak based on reviews of 
expert opinions and one case 
series study
20
 
 
Pitsios 2015
20
 
 
Beta-blocker therapy may be continued during 
VIT but the patient should be informed about 
possible risks 
IV C 
Weak based on two case 
series studies
26
 
24
 and expert 
consensus  
Stopping beta-blocker may 
even harmful for some 
patients 
Ruëff 2009
26
 
Ruëff 2010
24
 
ACE inhibitor therapy may be continued 
during VIT but the patient should be informed 
about possible risks  
IV 
 
C 
 
Weak based on two case 
series studies
25
 
24
 and expert 
consensus 
 
Stoevesandt 2014
25
 
Ruëff 2010
24
 
VIT can be recommended in high risk venom 
allergic patients when malignant disease is 
stable or in remission 
IV C 
Weak based on one case 
series study
34
 and expert 
consensus 
 
Wöhrl 2011
34
 
 
VIT can be recommended in patients with 
organ-specific autoimmune disorders when 
the underlying disease is stabilized 
V D 
Weak based on expert 
consensus 
Immune-suppressive 
medication may negatively 
influence effectiveness of VIT 
Expert consensus 
VIT cannot be recommended in patients with 
active, multi-system autoimmune disorders 
V D 
Weak based on expert 
consensus 
 Expert consensus 
Treatment with MAOIs is not a 
contraindication for VIT but caution is 
recommended with the use of adrenaline 
V D 
Weak based on case reports 
and expert consensus 
MAOIs are nowadays rarely 
prescribed 
Expert consensus 
VIT in children below 5 years of age should 
only be considered in the event of severe sting 
reactions and when the child is likely to be co-
operative          
IV C 
Weak based on one case 
series
38
 and expert 
consensus 
 Stritzke 2013
38
 
VIT should not be initiated during pregnancy, 
but well-tolerated ongoing VIT can be 
continued during pregnancy 
IV C 
Weak based on case series 
studies
39
 
40
 
 
Metzger 1978
39
 
Schwartz 1990
40
 
VIT may be recommended in patients with 
underlying systemic mastocytosis as it is safe 
and effective 
IV C 
Weak based on two case 
series
45
 
47
 
In few patients, side effects 
can be more frequent and 
severe 
Bonadonna 2008
45
, 
2013
47
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Table 3.  Recommendations: preparation and venom dose, pre-treatment with antihistamines, duration of treatment, carriage of adrenaline 
autoinjectors during/after VIT 
Recommendations for individuals with 
venom allergy 
Evidence 
level 
Grade of 
recommendati
on 
Strength of 
recommendation  
Other 
considerations 
Key reference 
Purified venom preparations can be 
recommended as they have a lower frequency 
of local and systemic adverse events than non-
purified aqueous preparations 
I  B 
Weak to moderate based 
on one RCT of 
moderate/low quality
63
 
 Bilo 2012
63
 
For the majority of patients, VIT with one venom 
may be recommended as sufficient for 
protection. In patients with a history of systemic 
sting reactions to different insects or with severe 
initial reactions and clearly double positive tests, 
VIT with two venoms (i.e Apis mellifera and 
Vespula or Vespula and Polistes) is 
recommended. 
IV C 
Weak based on one case 
series study
64
 and expert 
consensus 
 
 Stoevesandt 2013
64
 
Two venoms can be administered 
simultaneously in the left and right arm, 
respectively. However, in the case of systemic 
adverse events, VIT should be continued with 30 
minute intervals between injections 
V D 
Weak based on expert 
consensus 
 Expert consensus 
Pre-treatment with H1 antihistamines is 
recommended as it reduces large local reactions 
and to some extent also systemic adverse 
events 
I A 
Strong to moderate based 
on four RCTs, two of them 
were of high quality
68
 
67
,  
two of moderate quality 
66
 
65
 
 
Müller 2008
68
 
Reimers 2000
67
 
Brockow 1997
66
 
Berchtold 1992
65
 
It is recommended to administer a standard 
maintenance dose of 100µg venom II B 
Weak to moderate based 
on one CCT of 
moderate/low quality
88
 
 
Golden 1981
88
 
 
If patients still react to field stings or sting 
challenges, a dose increase to 200µg of venom 
can be recommended 
IV C 
Weak based on one case 
series study
91
 
 Ruëff 2001
91
 
It may be recommended to give injections every 
4 weeks in the first year of treatment, every 6 
V D 
Weak based on expert 
consensus
93
 
 Bonifazi 2005
93
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weeks in the second year, and in case of a 5 
year treatment every 8 weeks from year 3-5 
In the case of life-long therapy, 12 week 
intervals may be still safe and effective  II C 
Moderate based one CCT
94
 
and one CBA
95
 study 
 
Simioni 2013
94
 
Goldberg 2001
95
 
It can be recommended to perform VIT for at 
least 3 years. In patients with severe initial sting 
reactions, at least a 5-year treatment is 
recommended 
IV C 
Weak based on case series 
studies
98
 
99
 
101
 
 
Reisman 1993
98
 
Lerch 1998
99
 
Golden 1996
101
 
 
Life-long VIT may be recommended in highly 
exposed patients with bee venom allergy, 
patients with very severe initial sting reactions 
(Muller grade IV or grade III-IV according to Ring 
& Messmer), and patients with systemic side-
effects during VIT as they are major risk factors 
for relapse. 
IV C 
Weak based on case series 
studies
31
 
8
 
98
 
 
 
Ruëff 2013
31
; 2014
8
 
Reismann 1993
98
 
 
During and after VIT, AAI cannot be 
recommended in patients with mild to moderate 
initial sting reactions without risk factors for 
relapse 
V D 
Weak based on expert 
consensus  
 Expert consensus 
During and after VIT, AAI may be recommended 
in patients at risk of multiple stings or with risk 
factors for relapse  
V D 
Weak based on expert 
consensus  
 Expert consensus 
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Table 4. Recommendations: risk factors and management of side effects, risk factors for relapse  
Recommendations for individuals with 
venom allergy 
Evidence 
level 
Grade of 
recommendation 
Strength of 
recommendation  
Other considerations Key references 
It may be recommended that patients treated 
with bee venom and those on rapid up-dosing 
protocols should be closely observed for side 
effects as they are at a higher risk of 
experiencing adverse events 
 
IV C 
Weak based on case 
series studies
24
 
43
 
 
The intake of beta-
blockers or ACE 
inhibitors are not risk 
factors for adverse 
events during VIT. Also 
most of the 
mastocytosis patients 
tolerate VIT well 
  
 Ruëff 2010
24
 
 Mosbech 2000
43
 
It may be recommended that patients with 
severe initial sting reactions, high skin test 
reactivity, and high venom specific IgE levels 
do not require special precautions during VIT, 
as they are not associated with a higher risk 
of adverse events 
IV C 
Weak based on  
case series studies
25
 
24
 
84
 
  
 
Stoevesandt 
2014
25
 
Ruëff 2010
24
 
Lockey 1990
84
 
  
  
In case of VIT- related systemic adverse 
events during build-up phase, a temporary 
reduction of the venom dose (e.g. going one to 
two steps back in the protocol) may be 
recommended to avoid further adverse events 
V D 
Weak based on 
expert consensus 
 
 Expert consensus 
In case of repeated systemic adverse events 
during up-dosing, pre-treatment with 
Omalizumab may be recommended 
V D 
Weak based on case 
reports
70
 
71, 72
 
 
Stretz 2017
72
 
Kontou-Fili 2008
70
 
Schulze 2007
71
 
 
In case of VIT related LLR, it may be 
recommended to split dose in 2 injections or 
change injection site but not necessarily to 
reduce venom dose 
V D 
Weak based on 
expert consensus 
 Expert consensus 
Life-long VIT may be recommended in 
patients who relapsed after stopping VIT 
V D 
Weak based on 
expert consensus 
 Expert consensus 
It may be recommended to avoid insect 
stings during build-up phase by abiding by 
preventive measures (eg stop beekeeping) 
until maintenance dose is reached  
V D 
Weak based on 
expert consensus 
 Expert consensus 
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Table 5. Recommendations: monitoring of VIT 
Recommendations for 
individuals with venom allergy 
Evidence 
level 
Grade of 
recommendation 
Strength of 
recommendation  
Other considerations Key references 
In adults, a sting challenge can be 
recommended as the most 
reliable method to evaluate 
effectiveness of VIT  
IV C 
Weak based on case series 
studies
117
 
101
 
 
Van Halteren 1997
117
 
Golden 1996
101
 
 
If no sting challenge can be 
performed, it may be 
recommended to record outcomes 
of field stings to evaluate 
effectiveness of VIT 
V D 
Weak based on expert 
consensus 
 
Expert consensus 
 
It may not be recommended to 
determine venom specific IgE, IgG 
levels, BAT response and allergen-
blocking capacity to estimate the 
individual risk for relapse 
IV C 
Weak based on case series 
studies
99
 
112
 
100
 
 
 
Lerch 1998
99
 
Müller 1991
112
 
Keating 1991
100
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Table 6. Gaps in evidence 
 
Gaps Plan to address Priority 
Optimal duration of VIT in children and adults (for example, 3 versus 5 years or longer) RCTs High 
Evaluation of biomarkers such as sting challenges, component-resolved diagnosis, and BAT (inhibition) in 
assessing the clinical efficacy of VIT 
Prospective studies High  
Identification of biomarkers for the risk assessment for side effects and relapse Prospective studies High 
Comparison of different VIT up-dosing schedules, maintenance doses, and maintenance intervals in 
adults/children in terms of efficacy both short and long-term 
RCTs High 
Safety and efficacy of VIT in patients taking antihypertensive drugs (beta-blockers, ACEI)  Observational studies High 
Safety and efficacy of VIT in patients with elevated serum tryptase/mastocytosis verified by sting challenges RCTs High 
Comparison of purified and non-purified bee venom preparations in respect of safety and efficacy verified by 
sting challenges  
RCTs High 
Safety of the simultaneous application of two or more venoms during up-dosing and maintenance phase RCTs High 
Value of VIT on health-related quality of life compared to AAI in children and their parents RCTs Medium 
Assessing the cost-effectiveness of VIT Cost-effectiveness analysis of RCT Medium 
Safety of VIT in adults and children with concomitant disease such as cardiovascular disease Observational trials Medium 
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Table 7. Barriers and facilitators to implementation, audit criteria and resource implications of recommendations 
First-line intervention:  
 
VIT for venom allergic 
individuals  
  
 
Barriers to 
implementation 
Facilitators to 
implementation 
Audit criteria 
Resource 
implications 
Venom immunotherapy is highly 
clinically effective in adults and 
children with moderate to severe 
allergic reactions to hymenoptera 
stings 
   Failure to recognize 
severe allergic 
reactions (anaphylaxis) 
following hymenoptera 
stings 
Lack of knowledge 
amongst patients, 
caregivers and 
professionals about the 
availability of venom 
immunotherapy  
Concerns about side-
effects  
The hope that allergic 
reactions will subside 
with time or 
symptomatic 
treatments only                  
(e.g. AAI, 
antihistamines/ 
glucocorticosteroids) 
Education and 
training of 
emergency care 
doctors, general 
practitioners and 
other physicians on 
venom allergy and 
its grades of severity  
Information about 
need of follow-up 
visits with clinical 
allergists for 
diagnosis and  
management of 
venom allergy 
Information sheets 
for patients and 
caregivers 
 
Proportion of 
adults and 
children with 
moderate to 
severe SSR 
who are 
treated with 
VIT 
Proportion of 
adults and 
children 
experience 
relapses  
and/or side 
effects while 
on VIT 
 
Venom allergen 
immunotherapy 
(VIT) needs to be 
prescribed by 
clinical allergists 
and made available 
to patients. 
Patient education 
about self-treatment 
with adrenaline 
(AAI) before starting 
VIT is important and 
requires availability 
of trainer devices 
 
VIT is recommended in adult 
patients with systemic sting 
reactions confined to generalized 
skin symptoms if quality of life is 
impaired 
   Lack of knowledge 
amongst physicians, 
including clinical 
allergists about the 
indication of venom 
immunotherapy in 
these circumstances  
 
Education and 
training of 
physicians, and 
allergy specialists 
Information sheets 
for patients  
 
Proportion of 
patients 
experiencing 
impairment of 
QoL when 
venom allergy 
is confined to 
skin only who 
are treated 
with VIT 
Education and 
training of both 
physicians and 
patients 
Cost /Benefit profile 
needs to be 
established 
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Life-long VIT can be 
recommended in highly exposed 
patients with bee venom allergy, 
patients with very severe initial 
sting reactions (Muller grade IV or 
grade III-IV according to Ring & 
Messmer), and patients with 
systemic side-effects during VIT 
as they are major risk factors for 
relapse. 
   Lack of resources 
(professional and 
financial) 
Adherence to life-long 
VIT unrealistic  
Provision of 
insurance cover for 
life-long VIT within 
Europe 
Education and 
training of clinical 
allergists 
Education of patients 
in terms of sting 
exposure risk 
behavior; 
patient leaflets, 
smartphone “shot” 
reminder apps etc. 
Proportion of 
patients who 
adhere to life-
long (or 
prolonged, i.e. 
> 5 years ) VIT 
and proportion 
of patients 
consecutively 
tolerate 
hymenoptera 
stings 
Equipment of 
specialized allergy 
centers with skilled 
staff for successful 
administration of 
VIT  
Safety measures in 
place to minimize 
side effects in high 
risk patients 
Pre-treatment with H1 
antihistamines is recommended 
as it reduces large local reactions 
and to some extent also systemic 
adverse events 
   Lack of knowledge 
amongst health care 
professionals regarding 
pre-treatment  
Reluctance of patients 
Additional costs for 
health care system 
Education of 
healthcare 
professionals, and 
patients 
Proportion of 
patients with 
VIT who have 
antihistamine 
pre-treatment  
Prescription of 
antihistamines to be 
taken by patients 
prior to VIT  
AAI during and after VIT is 
recommended only in patients at 
risk of multiple stings or with risk 
factors for relapse 
   Lack of knowledge 
amongst health care 
professionals in terms 
of (non) prescribing 
AAI 
Risk behavior and 
misconception of 
patients 
Education of 
healthcare 
professionals, and 
patients 
Proportion of 
high risk 
patients 
carrying and 
administering 
intramuscular 
(AAI) during or 
after VIT 
Time to educate 
and train physicians 
and patients 
 
 
